Avtal nara, dags att agera.
2008-12-05 14:15, Edited at: 2010-06-11 11:58Please note: Community posts are written by its members and not by Redeye’s research department. As a reader you’re always encouraged to critically analyze the content.
Sektorn ar tillplattad , alla investmentbolag agerar kort, det bolag med flest och storst triggers innan arsskiftet ar Bioinvent.
Verkar som deal for BI204 Japan kan komma viken dag som helst, i borjan pa nov skrevs;
"The CEO confirmed that the Company is at the final stages of negotiations and a deal is expected this year. Because of Roche’s take-over attempt of Genentech, it would be customary to offer Roche the remaining license rights of Bi-204. The CEO confirmed that Japanese pharmaceuticals companies have shown interest in Bi-204 and negotiations with Roche’s Japanese partner Chugai are on-going. On September 29, the CEO stated to the news agency “Direkt” that a deal was not too distant away. "
Enbart upfrontpayment kommer ge minst 4:- per share, vilket ger 30% uppsida.
Andra triggers denna manad;
tb 402 uppstart Phase II
Tecniskt ser det mer an intresnt ut, aktien vander upp fran en forsta stigande botten med en teknisk stark stodniva strax under sig, inga motstand att tala om innan 18 SEK.
Mvh SC